tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Personal Finance CenterMortgagesLoansInvesting & RetirementSpending & Savings
Calculators
401k Retirement CalculatorMortgage Calculator
Popular
Compound Interest CalculatorDollar Cost Averaging
New
Student Loan CalculatorAuto Loan Calculator
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

NBIX Stock Latest News

Neurocrine launches Ingrezza capsules for dysphagia
The FlyNeurocrine launches Ingrezza capsules for dysphagia
3d ago
NBIX
Neurocrine price target raised to $170 from $160 at Morgan Stanley
PremiumThe Fly
Neurocrine price target raised to $170 from $160 at Morgan Stanley
9d ago
NBIX
Neurocrine price target raised to $173 from $169 at JPMorgan
PremiumThe Fly
Neurocrine price target raised to $173 from $169 at JPMorgan
11d ago
NBIX
Jefferies says Neurocrine, Alkermes not seeing Sublocade-like impact on Medicaid
PremiumThe Fly
Jefferies says Neurocrine, Alkermes not seeing Sublocade-like impact on Medicaid
12d ago
ALKS
INDV
Neurocrine announces FDA accepted two NDAs
PremiumThe Fly
Neurocrine announces FDA accepted two NDAs
20d ago
NBIX
Neurocrine presented CAHtalyst Phase 3 studies at ENDO 2024
PremiumThe FlyNeurocrine presented CAHtalyst Phase 3 studies at ENDO 2024
2M ago
NBIX
Neurocrine announces CAHtalyst Pediatric Phase 3 study met primary endpoint
PremiumThe Fly
Neurocrine announces CAHtalyst Pediatric Phase 3 study met primary endpoint
2M ago
NBIX
Neurocrine announces CAHtalyst Phase 3 study met primary endpoint
PremiumThe Fly
Neurocrine announces CAHtalyst Phase 3 study met primary endpoint
2M ago
NBIX
Neurocrine Biosciences Announces CEO Retirement and Succession
PremiumCompany Announcements
Neurocrine Biosciences Announces CEO Retirement and Succession
2M ago
8K
NBIX
Neurocrine CEO Kevin Gorman, Ph.D to retire, Kyle Gano, Ph.D to succeed
PremiumThe Fly
Neurocrine CEO Kevin Gorman, Ph.D to retire, Kyle Gano, Ph.D to succeed
2M ago
NBIX
Neurocrine price target raised to $193 from $174 at UBS
PremiumThe Fly
Neurocrine price target raised to $193 from $174 at UBS
2M ago
NBIX
RBC still sees gradual uptake for Neurocrine after competitor data
PremiumThe Fly
RBC still sees gradual uptake for Neurocrine after competitor data
2M ago
CRNX
NBIX
Neurocrine competitive data should be kept in perspective, says Evercore
PremiumThe FlyNeurocrine competitive data should be kept in perspective, says Evercore
2M ago
CRNX
NBIX
Neurocrine announces publication of data from Phase 3 KINECT-4 study of INGREZZA
PremiumThe Fly
Neurocrine announces publication of data from Phase 3 KINECT-4 study of INGREZZA
2M ago
NBIX
Neurocrine presents baseline data of CAH program
PremiumThe Fly
Neurocrine presents baseline data of CAH program
2M ago
NBIX
Neurocrine initiated with an Outperform at Evercore ISI
PremiumThe Fly
Neurocrine initiated with an Outperform at Evercore ISI
2M ago
NBIX
Neurocrine presents CAHtalyst adult study baseline characteristics, data
PremiumThe Fly
Neurocrine presents CAHtalyst adult study baseline characteristics, data
2M ago
NBIX
Neurocrine announces initiation of Phase 1 study evaluating NBI-1076986
PremiumThe Fly
Neurocrine announces initiation of Phase 1 study evaluating NBI-1076986
2M ago
NBIX
Neurocrine initiates Phase 1 clinical study of NBI-1117567 in healthy adults
PremiumThe Fly
Neurocrine initiates Phase 1 clinical study of NBI-1117567 in healthy adults
2M ago
NBIX
Neurocrine presents data from CAHtalyst Pediatric Phase 3 clinical study
PremiumThe FlyNeurocrine presents data from CAHtalyst Pediatric Phase 3 clinical study
3M ago
NBIX
Neurocrine price target raised to $150 from $140 at Citi
PremiumThe Fly
Neurocrine price target raised to $150 from $140 at Citi
3M ago
NBIX
Neurocrine price target raised to $164 from $154 at Canaccord
PremiumThe Fly
Neurocrine price target raised to $164 from $154 at Canaccord
3M ago
NBIX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >